Improving the Understanding and Management of Adverse Events During Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma

Sunday, September 29
Time: 6:30 – 8:00 am
Location: Jasmine AB

Speakers

David J. Hermel, MD
Clinical Instructor of Medicine, Bone Marrow Transplant and Cellular Therapy Program, Scripps Clinic, La Jolla, CA

Monica K. Wattana, MD
Associate Professor, Director of Education, Department of Emergency Medicine, UT MD Anderson Cancer Center, Houston, Texas

Symposium Information

Multiple myeloma (MM), the second most common hematological malignancy in
the world, affects 1 to 5 out of 100,000 individuals per year primarily in patients
65 years of age or older. There is currently no cure and patients reaching complete response (CR) to treatment will eventually relapse. MM patients with relapsing and/or refractory (R/R) disease are exposed for prolonged periods of time to multiple drugs in varying combinations, which increases their risk of developing toxicity and treatment-related adverse events (TRAEs). With the increasing implementation of novel therapies, including CAR T-cell therapy and bispecific antibodies (BsAbs), to the growing treatment armamentarium for MM, emergency medical physicians, advanced practice practitioners (APPs), and other emergency medicine health professionals must remain apprised of any and all TRAEs. Clinicians must be prepared to both quickly and accurately diagnose and treat life-threatening events including immune effector cell-associated neurotoxicity syndrome neurotoxicity (ICANS) and cytokine release syndrome (CRS). With these challenges in mind, this symposium will focus on the safety and efficacy of current and emerging immunotherapies, and patient-specific strategies related to risk factors, toxicities, and AE management to assist emergency providers in mitigating untoward TRAEs as they apply to MM.

Learning Objectives

• Summarize real-world clinical data associated with newer and emerging immunotherapeutic options in R/R MM, including CAR T-cell therapy and BsAbs, and their potential TRAEs
• Describe how to promptly recognize, triage, diagnose, and manage the most common TRAEs and toxicities associated with R/R MM therapies
• Evaluate current guidelines/protocols available to address AEs associated with the disease process as well as TRAEs in MM
• Implement strategies for multidisciplinary care coordination for managing AEs

Commercial Support

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Legend Biotech.

Continuing Education

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.

Physicians

HMP Education designates this internet live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

This continuing nursing education internet live activity awards 1.5 contact hour(s).

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.5 contact hour(s).

Nurse Practitioners

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by the ACCME.

Physician Assistants

HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet live activity is designated for 1.5 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.